Targeting asparagine and cysteine in SARS-CoV-2 variants and human pro-inflammatory mediators to alleviate COVID-19 severity; a cross-section and in-silico study

Abstract To date, COVID-19 continues to pose a global health challenge, with substantial morbidity, mortality, and long-term post-COVID-19 complications threatening public health resilience. During the early pandemic, the IL-6 inhibitor (tocilizumab) was the widely used approved immunotherapy for cr...

詳細記述

書誌詳細

主要な著者:	Hewida H. Fadel, Hadeer Adel EL-Esseily, Mohammed Abd EL-Rahman Ahmed, Mohammed Ahmed Khamis Mohamed, Mohamed Nabil Roushdy, Amr ElSherif, Kareem Mahamoud Gharbeya, Hadeel Said Abdelsalam
フォーマット:	Artigo
言語:	Inglês
出版事項:	Nature Portfolio 2025-11-01
シリーズ:	Scientific Reports
主題:	SARS-CoV-2 COVID-19 Interleukin-17 Asparaginase Cysteine Phytotherapies
オンライン･アクセス:	https://doi.org/10.1038/s41598-025-19359-y
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!